1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Hepatitis D Market
2.1.1. Global Hepatitis D Market, By Diagnostic Tests
2.1.2. Global Hepatitis D Market, By Treatment Modalities
2.1.3. Global Hepatitis D Market, By Antiviral Drugs
2.1.4. Global Hepatitis D Market, By Disease Severity
2.1.5. Global Hepatitis D Market, By Patient Population
2.1.6. Global Hepatitis D Market, By End-users
2.1.7. Global Hepatitis D Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Hepatitis D Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Hepatitis D Market Drivers
3.2.2. Hepatitis D Market Restraints
3.2.3. Hepatitis D Market Opportunities
3.2.4. Major Hepatitis D Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Diagnostic Tests
3.5.2. Treatment Modalities
3.5.3. Antiviral Drugs
3.5.4. Disease Severity
3.5.5. Patient Population
3.5.6. End-users
3.5.7. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Global Hepatitis D Market: Company Market Share, Value 2022
4.1.2. Global Hepatitis D Market: Top 6 Company Market Share, Value 2022
4.1.3. Global Hepatitis D Market: Top 3 Company Market Share, Value 2022
4.2. Global Hepatitis D Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Hepatitis D Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Hepatitis D Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Hepatitis D Market, By Diagnostic Tests
8.1. Global Hepatitis D Market Overview, by Diagnostic Tests
8.1.1. Global Hepatitis D Market Revenue Share, By Diagnostic Tests, 2022 Vs 2030 (in %)
8.2. Serology Tests
8.2.1. Global Hepatitis D Market, By Serology Tests, By Region, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for Serology Tests
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Nucleic Acid Tests
8.3.1. Global Hepatitis D Market, By Nucleic Acid Tests, By Region, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for Nucleic Acid Tests
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Liver Function Tests
8.4.1. Global Hepatitis D Market, By Liver Function Tests, By Region, 2017-2030 (US$ Mn)
8.4.2. Market Dynamics for Liver Function Tests
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Imaging Tests
8.5.1. Global Hepatitis D Market, By Imaging Tests, By Region, 2017-2030 (US$ Mn)
8.5.2. Market Dynamics for Imaging Tests
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
9. Global Hepatitis D Market, By Treatment Modalities
9.1. Global Hepatitis D Market Overview, by Treatment Modalities
9.1.1. Global Hepatitis D Market Revenue Share, By Treatment Modalities, 2022 Vs 2030 (in %)
9.2. Antiviral Therapy
9.2.1. Global Hepatitis D Market, By Antiviral Therapy, By Region, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for Antiviral Therapy
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Liver Supportive Care
9.3.1. Global Hepatitis D Market, By Liver Supportive Care, By Region, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for Liver Supportive Care
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Liver Transplantation
9.4.1. Global Hepatitis D Market, By Liver Transplantation, By Region, 2017-2030 (US$ Mn)
9.4.2. Market Dynamics for Liver Transplantation
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
10. Global Hepatitis D Market, By Antiviral Drugs
10.1. Global Hepatitis D Market Overview, by Antiviral Drugs
10.1.1. Global Hepatitis D Market Revenue Share, By Antiviral Drugs, 2022 Vs 2030 (in %)
10.2. Pegylated Interferon Alpha
10.2.1. Global Hepatitis D Market, By Pegylated Interferon Alpha, By Region, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for Pegylated Interferon Alpha
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Bulevirtide
10.3.1. Global Hepatitis D Market, By Bulevirtide, By Region, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Bulevirtide
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Experimental Therapies
10.4.1. Global Hepatitis D Market, By Experimental Therapies, By Region, 2017-2030 (US$ Mn)
10.4.2. Market Dynamics for Experimental Therapies
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
11. Global Hepatitis D Market, By Disease Severity
11.1. Global Hepatitis D Market Overview, by Disease Severity
11.1.1. Global Hepatitis D Market Revenue Share, By Disease Severity, 2022 Vs 2030 (in %)
11.2. Chronic Hepatitis D
11.2.1. Global Hepatitis D Market, By Chronic Hepatitis D, By Region, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Chronic Hepatitis D
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Acute Hepatitis D
11.3.1. Global Hepatitis D Market, By Acute Hepatitis D, By Region, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Acute Hepatitis D
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Advanced Liver Disease
11.4.1. Global Hepatitis D Market, By Advanced Liver Disease, By Region, 2017-2030 (US$ Mn)
11.4.2. Market Dynamics for Advanced Liver Disease
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
12. Global Hepatitis D Market, By Patient Population
12.1. Global Hepatitis D Market Overview, by Patient Population
12.1.1. Global Hepatitis D Market Revenue Share, By Patient Population, 2022 Vs 2030 (in %)
12.2. HBV Co-Infection
12.2.1. Global Hepatitis D Market, By HBV Co-Infection, By Region, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for HBV Co-Infection
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Mono-Infection
12.3.1. Global Hepatitis D Market, By Mono-Infection, By Region, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Mono-Infection
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
13. Global Hepatitis D Market, By End-users
13.1. Global Hepatitis D Market Overview, by End-users
13.1.1. Global Hepatitis D Market Revenue Share, By End-users, 2022 Vs 2030 (in %)
13.2. Hospitals and Clinics
13.2.1. Global Hepatitis D Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)
13.2.2. Market Dynamics for Hospitals and Clinics
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Research Institutions
13.3.1. Global Hepatitis D Market, By Research Institutions, By Region, 2017-2030 (US$ Mn)
13.3.2. Market Dynamics for Research Institutions
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends
14. Global Hepatitis D Market, By Region
14.1. Global Hepatitis D Market Overview, by Region
14.1.1. Global Hepatitis D Market, By Region, 2022 vs 2030 (in%)
14.2. Diagnostic Tests
14.2.1. Global Hepatitis D Market, By Diagnostic Tests, 2017-2030 (US$ Mn)
14.3. Treatment Modalities
14.3.1. Global Hepatitis D Market, By Treatment Modalities, 2017-2030 (US$ Mn)
14.4. Antiviral Drugs
14.4.1. Global Hepatitis D Market, By Antiviral Drugs, 2017-2030 (US$ Mn)
14.5. Disease Severity
14.5.1. Global Hepatitis D Market, By Disease Severity, 2017-2030 (US$ Mn)
14.6. Patient Population
14.6.1. Global Hepatitis D Market, By Patient Population, 2017-2030 (US$ Mn)
14.7. End-users
14.7.1. Global Hepatitis D Market, By End-users, 2017-2030 (US$ Mn)
15. North America Hepatitis D Market Analysis
15.1. Overview
15.1.1. Market Dynamics for North America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. North America Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. North America Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. North America Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. North America Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
15.5.1. Overview
15.5.2. SRC Analysis
15.6. North America Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
15.6.1. Overview
15.6.2. SRC Analysis
15.7. North America Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
15.7.1. Overview
15.7.2. SRC Analysis
15.8. North America Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
15.8.1. North America Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
15.8.2. U.S.
15.8.3. Canada
15.8.4. Mexico
16. Europe Hepatitis D Market Analysis
16.1. Overview
16.1.1. Market Dynamics for Europe
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Europe Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Europe Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Europe Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Europe Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. Europe Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. Europe Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
16.7.1. Overview
16.7.2. SRC Analysis
16.8. Europe Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
16.8.1. Europe Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
16.8.2. UK
16.8.3. France
16.8.4. Germany
16.8.5. Italy
16.8.6. Spain
16.8.7. Benelux
16.8.8. Russia
16.8.9. Rest of Europe
17. Asia Pacific Hepatitis D Market Analysis
17.1. Overview
17.1.1. Market Dynamics for Asia Pacific
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Asia Pacific Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Asia Pacific Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Asia Pacific Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Asia Pacific Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Asia Pacific Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Asia Pacific Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
17.7.1. Overview
17.7.2. SRC Analysis
17.8. Asia Pacific Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
17.8.1. Asia Pacific Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
17.8.2. China
17.8.3. Japan
17.8.4. India
17.8.5. South Korea
17.8.6. South East Asia
17.8.7. Rest of Asia Pacific
18. Latin America Hepatitis D Market Analysis
18.1. Overview
18.1.1. Market Dynamics for Latin America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Latin America Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Latin America Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Latin America Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Latin America Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Latin America Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Latin America Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
18.7.1. Overview
18.7.2. SRC Analysis
18.8. Latin America Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
18.8.1. Latin America Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
18.8.2. Brazil
18.8.3. Argentina
18.8.4. Rest of Latin America
19. Middle East Hepatitis D Market Analysis
19.1. Overview
19.1.1. Market Dynamics for Middle East
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Middle East Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Middle East Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Middle East Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Middle East Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Middle East Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Middle East Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
19.7.1. Overview
19.7.2. SRC Analysis
19.8. Middle East Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
19.8.1. Middle East Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
19.8.2. UAE
19.8.3. Saudi Arabia
19.8.4. Rest of Middle East
20. Africa Hepatitis D Market Analysis
20.1. Overview
20.1.1. Market Dynamics for Africa
20.1.1.1. Drivers
20.1.1.2. Restraints
20.1.1.3. Opportunities
20.1.1.4. Trends
20.2. Africa Hepatitis D Market, by Diagnostic Tests, 2017-2030(US$ Mn)
20.2.1. Overview
20.2.2. SRC Analysis
20.3. Africa Hepatitis D Market, by Treatment Modalities, 2017-2030(US$ Mn)
20.3.1. Overview
20.3.2. SRC Analysis
20.4. Africa Hepatitis D Market, by Antiviral Drugs, 2017-2030(US$ Mn)
20.4.1. Overview
20.4.2. SRC Analysis
20.5. Africa Hepatitis D Market, by Disease Severity, 2017-2030(US$ Mn)
20.5.1. Overview
20.5.2. SRC Analysis
20.6. Africa Hepatitis D Market, by Patient Population, 2017-2030(US$ Mn)
20.6.1. Overview
20.6.2. SRC Analysis
20.7. Africa Hepatitis D Market, by End-users, 2017-2030(US$ Mn)
20.7.1. Overview
20.7.2. SRC Analysis
20.8. Africa Hepatitis D Market, by Country, 2017-2030 (US$ Mn)
20.8.1. Africa Hepatitis D Market, by Country, 2022 Vs 2030 (in%)
20.8.2. South Africa
20.8.3. Egypt
20.8.4. Rest of Africa
21. Company Profiles
21.1. BIOSIDUS
21.1.1. Company Overview
21.1.2. Products/Services Portfolio
21.1.3. Geographical Presence
21.1.4. SWOT Analysis
21.1.5. Financial Summary
21.1.5.1. Market Revenue and Net Profit (2019-2022)
21.1.5.2. Business Segment Revenue Analysis
21.1.5.3. Geographical Revenue Analysis
21.2. F. Hoffmann-La Roche Ltd
21.3. anoGen Healthcare Pvt. Ltd.
21.4. AMEGA Biotech
21.5. Rhein-Minapharm
21.6. PROBIOMED SA de CV
21.7. 3SBio Group
21.8. Eiger BioPharmaceuticals
21.9. Hepion Pharmaceuticals, Inc.
21.10. Antios Therapeutics, Inc.
21.11. PharmaEssentia Corporation
21.12. Replicor
21.13. Janssen Pharmaceuticals, Inc.
21.14. Apotex Corp.
21.15. Mylan N.V
21.16. Aurobindo Pharma Limited
21.17. Gilead Sciences, Inc.
21.18. GlaxoSmithKline
21.19. Zydus Pharmaceuticals
21.20. Others
22. Research Methodology
22.1. Research Methodology
22.2. Phase I – Secondary Research
22.3. Phase II – Data Modelling
22.3.1. Company Share Analysis Model
22.3.2. Revenue Based Modelling
22.4. Phase III – Primary Research
22.5. Research Limitations
22.5.1. Assumptions
List of Figures
FIG. 1 Global Hepatitis D Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Hepatitis D Market Segmentation
FIG. 4 Global Hepatitis D Market, by Diagnostic Tests, 2022 (US$ Mn)
FIG. 5 Global Hepatitis D Market, by Treatment Modalities, 2022 (US$ Mn)
FIG. 6 Global Hepatitis D Market, by Antiviral Drugs, 2022 (US$ Mn)
FIG. 7 Global Hepatitis D Market, by Disease Severity, 2022 (US$ Mn)
FIG. 8 Global Hepatitis D Market, by Patient Population, 2022 (US$ Mn)
FIG. 9 Global Hepatitis D Market, by End-users, 2022 (US$ Mn)
FIG. 10 Global Hepatitis D Market, by Geography, 2022 (US$ Mn)
FIG. 11 Attractive Investment Proposition, by Diagnostic Tests, 2022
FIG. 12 Attractive Investment Proposition, by Treatment Modalities, 2022
FIG. 13 Attractive Investment Proposition, by Antiviral Drugs, 2022
FIG. 14 Attractive Investment Proposition, by Disease Severity, 2022
FIG. 15 Attractive Investment Proposition, by Patient Population, 2022
FIG. 16 Attractive Investment Proposition, by End-users, 2022
FIG. 17 Attractive Investment Proposition, by Geography, 2022
FIG. 18 Global Market Share Analysis of Key Hepatitis D Market Manufacturers, 2022
FIG. 19 Global Market Positioning of Key Hepatitis D Market Manufacturers, 2022
FIG. 20 Global Hepatitis D Market Value Contribution, By Diagnostic Tests, 2022 & 2030 (Value %)
FIG. 21 Global Hepatitis D Market, by Serology Tests, Value, 2017-2030 (US$ Mn)
FIG. 22 Global Hepatitis D Market, by Nucleic Acid Tests, Value, 2017-2030 (US$ Mn)
FIG. 23 Global Hepatitis D Market, by Liver Function Tests, Value, 2017-2030 (US$ Mn)
FIG. 24 Global Hepatitis D Market, by Imaging Tests, Value, 2017-2030 (US$ Mn)
FIG. 25 Global Hepatitis D Market Value Contribution, By Treatment Modalities, 2022 & 2030 (Value %)
FIG. 26 Global Hepatitis D Market, by Antiviral Therapy, Value, 2017-2030 (US$ Mn)
FIG. 27 Global Hepatitis D Market, by Liver Supportive Care, Value, 2017-2030 (US$ Mn)
FIG. 28 Global Hepatitis D Market, by Liver Transplantation, Value, 2017-2030 (US$ Mn)
FIG. 29 Global Hepatitis D Market Value Contribution, By Antiviral Drugs, 2022 & 2030 (Value %)
FIG. 30 Global Hepatitis D Market, by Pegylated Interferon Alpha, Value, 2017-2030 (US$ Mn)
FIG. 31 Global Hepatitis D Market, by Bulevirtide, Value, 2017-2030 (US$ Mn)
FIG. 32 Global Hepatitis D Market, by Experimental Therapies, Value, 2017-2030 (US$ Mn)
FIG. 33 Global Hepatitis D Market Value Contribution, By Disease Severity, 2022 & 2030 (Value %)
FIG. 34 Global Hepatitis D Market, by Chronic Hepatitis D, Value, 2017-2030 (US$ Mn)
FIG. 35 Global Hepatitis D Market, by Acute Hepatitis D, Value, 2017-2030 (US$ Mn)
FIG. 36 Global Hepatitis D Market, by Advanced Liver Disease, Value, 2017-2030 (US$ Mn)
FIG. 37 Global Hepatitis D Market Value Contribution, By Patient Population, 2022 & 2030 (Value %)
FIG. 38 Global Hepatitis D Market, by HBV Co-Infection, Value, 2017-2030 (US$ Mn)
FIG. 39 Global Hepatitis D Market, by Mono-Infection, Value, 2017-2030 (US$ Mn)
FIG. 40 Global Hepatitis D Market Value Contribution, By End-users, 2022 & 2030 (Value %)
FIG. 41 Global Hepatitis D Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)
FIG. 42 Global Hepatitis D Market, by Research Institutions, Value, 2017-2030 (US$ Mn)
FIG. 43 North America Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 44 U.S. Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 45 Canada Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 46 Mexico Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 47 Europe Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 48 Germany Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 49 France Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 50 U.K. Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 51 Italy Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 52 Spain Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 53 Benelux Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 54 Russia Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 55 Rest of Europe Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 56 Asia Pacific Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 57 China Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 58 Japan Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 59 India Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 60 South Korea Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 61 South-East Asia Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 62 Rest of Asia Pacific Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 63 Latin America Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 64 Brazil Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 65 Argentina Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 66 Rest of Latin America Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 67 Middle East Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 68 UAE Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 69 Saudi Arabia Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 70 Rest of Middle East Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 71 Africa Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 72 South Africa Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 73 Egypt Hepatitis D Market, 2017-2030 (US$ Mn)
FIG. 74 Rest of Africa Hepatitis D Market, 2017-2030 (US$ Mn)
List of Tables
TABLE 1 Market Snapshot: Global Hepatitis D Market
TABLE 2 Global Hepatitis D Market: Market Drivers Impact Analysis
TABLE 3 Global Hepatitis D Market: Market Restraints Impact Analysis
TABLE 4 Global Hepatitis D Market, by Competitive Benchmarking, 2022
TABLE 5 Global Hepatitis D Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Hepatitis D Market, by Key Strategies Analysis, 2022
TABLE 7 Global Hepatitis D Market, by Serology Tests, By Region, 2017-2022 (US$ Mn)
TABLE 8 Global Hepatitis D Market, by Serology Tests, By Region, 2023-2030 (US$ Mn)
TABLE 9 Global Hepatitis D Market, by Nucleic Acid Tests, By Region, 2017-2022 (US$ Mn)
TABLE 10 Global Hepatitis D Market, by Nucleic Acid Tests, By Region, 2023-2030 (US$ Mn)
TABLE 11 Global Hepatitis D Market, by Liver Function Tests, By Region, 2017-2022 (US$ Mn)
TABLE 12 Global Hepatitis D Market, by Liver Function Tests, By Region, 2023-2030 (US$ Mn)
TABLE 13 Global Hepatitis D Market, by Imaging Tests, By Region, 2017-2022 (US$ Mn)
TABLE 14 Global Hepatitis D Market, by Imaging Tests, By Region, 2023-2030 (US$ Mn)
TABLE 15 Global Hepatitis D Market, by Antiviral Therapy, By Region, 2017-2022 (US$ Mn)
TABLE 16 Global Hepatitis D Market, by Antiviral Therapy, By Region, 2023-2030 (US$ Mn)
TABLE 17 Global Hepatitis D Market, by Liver Supportive Care, By Region, 2017-2022 (US$ Mn)
TABLE 18 Global Hepatitis D Market, by Liver Supportive Care, By Region, 2023-2030 (US$ Mn)
TABLE 19 Global Hepatitis D Market, by Liver Transplantation, By Region, 2017-2022 (US$ Mn)
TABLE 20 Global Hepatitis D Market, by Liver Transplantation, By Region, 2023-2030 (US$ Mn)
TABLE 21 Global Hepatitis D Market, by Pegylated Interferon Alpha, By Region, 2017-2022 (US$ Mn)
TABLE 22 Global Hepatitis D Market, by Pegylated Interferon Alpha, By Region, 2023-2030 (US$ Mn)
TABLE 23 Global Hepatitis D Market, by Bulevirtide, By Region, 2017-2022 (US$ Mn)
TABLE 24 Global Hepatitis D Market, by Bulevirtide, By Region, 2023-2030 (US$ Mn)
TABLE 25 Global Hepatitis D Market, by Experimental Therapies, By Region, 2017-2022 (US$ Mn)
TABLE 26 Global Hepatitis D Market, by Experimental Therapies, By Region, 2023-2030 (US$ Mn)
TABLE 27 Global Hepatitis D Market, by Chronic Hepatitis D, By Region, 2017-2022 (US$ Mn)
TABLE 28 Global Hepatitis D Market, by Chronic Hepatitis D, By Region, 2023-2030 (US$ Mn)
TABLE 29 Global Hepatitis D Market, by Acute Hepatitis D, By Region, 2017-2022 (US$ Mn)
TABLE 30 Global Hepatitis D Market, by Acute Hepatitis D, By Region, 2023-2030 (US$ Mn)
TABLE 31 Global Hepatitis D Market, by Advanced Liver Disease, By Region, 2023-2030 (US$ Mn)
TABLE 32 Global Hepatitis D Market, by Advanced Liver Disease, By Region, 2023-2030 (US$ Mn)
TABLE 33 Global Hepatitis D Market, by HBV Co-Infection, By Region, 2017-2022 (US$ Mn)
TABLE 34 Global Hepatitis D Market, by HBV Co-Infection, By Region, 2023-2030 (US$ Mn)
TABLE 35 Global Hepatitis D Market, by Mono-Infection, By Region, 2017-2022 (US$ Mn)
TABLE 36 Global Hepatitis D Market, by Mono-Infection, By Region, 2023-2030 (US$ Mn)
TABLE 37 Global Hepatitis D Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)
TABLE 38 Global Hepatitis D Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)
TABLE 39 Global Hepatitis D Market, by Research Institutions, By Region, 2017-2022 (US$ Mn)
TABLE 40 Global Hepatitis D Market, by Research Institutions, By Region, 2023-2030 (US$ Mn)
TABLE 41 Global Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 42 Global Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 43 Global Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 44 Global Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 45 Global Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 46 Global Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 47 Global Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 48 Global Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 49 Global Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 50 Global Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 51 Global Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 52 Global Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 53 Global Hepatitis D Market, by Region, 2017-2022 (US$ Mn)
TABLE 54 Global Hepatitis D Market, by Region, 2023-2030 (US$ Mn)
TABLE 55 North America Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 56 North America Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 57 North America Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 58 North America Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 59 North America Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 60 North America Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 61 North America Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 62 North America Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 63 North America Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 64 North America Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 65 North America Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 66 North America Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 67 North America Hepatitis D Market, by Country, 2017-2022 (US$ Mn)
TABLE 68 North America Hepatitis D Market, by Country, 2023-2030 (US$ Mn)
TABLE 69 United States Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 70 United States Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 71 United States Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 72 United States Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 73 United States Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 74 United States Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 75 United States Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 76 United States Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 77 United States Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 78 United States Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 79 United States Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 80 United States Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 81 Canada Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 82 Canada Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 83 Canada Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 84 Canada Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 85 Canada Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 86 Canada Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 87 Canada Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 88 Canada Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 89 Canada Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 90 Canada Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 91 Canada Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 92 Canada Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 93 Mexico Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 94 Mexico Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 95 Mexico Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 96 Mexico Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 97 Mexico Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 98 Mexico Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 99 Mexico Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 100 Mexico Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 101 Mexico Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 102 Mexico Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 103 Mexico Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 104 Mexico Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 105 Europe Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 106 Europe Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 107 Europe Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 108 Europe Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 109 Europe Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 110 Europe Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 111 Europe Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 112 Europe Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 113 Europe Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 114 Europe Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 115 Europe Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 116 Europe Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 117 Europe Hepatitis D Market, by Country, 2017-2022 (US$ Mn)
TABLE 118 Europe Hepatitis D Market, by Country, 2023-2030 (US$ Mn)
TABLE 119 Germany Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 120 Germany Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 121 Germany Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 122 Germany Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 123 Germany Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 124 Germany Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 125 Germany Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 126 Germany Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 127 Germany Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 128 Germany Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 129 Germany Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 130 Germany Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 131 France Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 132 France Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 133 France Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 134 France Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 135 France Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 136 France Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 137 France Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 138 France Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 139 France Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 140 France Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 141 France Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 142 France Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 143 United Kingdom Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 144 United Kingdom Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 145 United Kingdom Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 146 United Kingdom Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 147 United Kingdom Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 148 United Kingdom Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 149 United Kingdom Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 150 United Kingdom Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 151 United Kingdom Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 152 United Kingdom Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 153 United Kingdom Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 154 United Kingdom Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 155 Italy Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 156 Italy Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 157 Italy Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 158 Italy Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 159 Italy Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 160 Italy Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 161 Italy Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 162 Italy Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 163 Italy Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 164 Italy Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 165 Italy Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 166 Italy Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 167 Spain Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 168 Spain Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 169 Spain Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 170 Spain Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 171 Spain Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 172 Spain Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 173 Spain Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 174 Spain Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 175 Spain Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 176 Spain Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 177 Spain Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 178 Spain Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 179 Benelux Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 180 Benelux Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 181 Benelux Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 182 Benelux Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 183 Benelux Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 184 Benelux Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 185 Benelux Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 186 Benelux Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 187 Benelux Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 188 Benelux Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 189 Benelux Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 190 Benelux Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 191 Russia Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 192 Russia Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 193 Russia Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 194 Russia Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 195 Russia Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 196 Russia Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 197 Russia Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 198 Russia Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 199 Russia Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 200 Russia Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 201 Russia Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 202 Russia Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 203 Rest of Europe Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 204 Rest of Europe Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 205 Rest of Europe Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 206 Rest of Europe Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 207 Rest of Europe Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 208 Rest of Europe Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 209 Rest of Europe Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 210 Rest of Europe Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 211 Rest of Europe Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 212 Rest of Europe Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 213 Rest of Europe Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 214 Rest of Europe Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 215 Asia Pacific Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 216 Asia Pacific Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 217 Asia Pacific Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 218 Asia Pacific Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 219 Asia Pacific Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 220 Asia Pacific Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 221 Asia Pacific Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 222 Asia Pacific Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 223 Asia Pacific Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 224 Asia Pacific Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 225 Asia Pacific Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 226 Asia Pacific Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 227 China Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 228 China Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 229 China Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 230 China Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 231 China Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 232 China Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 233 China Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 234 China Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 235 China Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 236 China Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 237 China Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 238 China Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 239 Japan Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 240 Japan Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 241 Japan Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 242 Japan Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 243 Japan Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 244 Japan Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 245 Japan Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 246 Japan Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 247 Japan Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 248 Japan Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 249 Japan Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 250 Japan Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 251 India Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 252 India Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 253 India Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 254 India Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 255 India Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 256 India Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 257 India Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 258 India Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 259 India Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 260 India Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 261 India Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 262 India Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 263 South Korea Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 264 South Korea Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 265 South Korea Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 266 South Korea Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 267 South Korea Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 268 South Korea Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 269 South Korea Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 270 South Korea Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 271 South Korea Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 272 South Korea Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 273 South Korea Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 274 South Korea Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 275 South-East Asia Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 276 South-East Asia Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 277 South-East Asia Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 278 South-East Asia Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 279 South-East Asia Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 280 South-East Asia Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 281 South-East Asia Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 282 South-East Asia Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 283 South-East Asia Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 284 South-East Asia Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 285 South-East Asia Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 286 South-East Asia Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 287 Rest of Asia Pacific Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 288 Rest of Asia Pacific Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 289 Rest of Asia Pacific Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 290 Rest of Asia Pacific Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 291 Rest of Asia Pacific Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 292 Rest of Asia Pacific Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 293 Rest of Asia Pacific Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 294 Rest of Asia Pacific Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 295 Rest of Asia Pacific Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 296 Rest of Asia Pacific Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 297 Rest of Asia Pacific Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 298 Rest of Asia Pacific Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 299 Latin America Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 300 Latin America Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 301 Latin America Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 302 Latin America Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 303 Latin America Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 304 Latin America Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 305 Latin America Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 306 Latin America Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 307 Latin America Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 308 Latin America Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 309 Latin America Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 310 Latin America Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 311 Brazil Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 312 Brazil Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 313 Brazil Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 314 Brazil Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 315 Brazil Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 316 Brazil Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 317 Brazil Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 318 Brazil Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 319 Brazil Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 320 Brazil Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 321 Brazil Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 322 Brazil Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 323 Argentina Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 324 Argentina Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 325 Argentina Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 326 Argentina Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 327 Argentina Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 328 Argentina Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 329 Argentina Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 330 Argentina Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 331 Argentina Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 332 Argentina Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 333 Argentina Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 334 Argentina Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 335 Rest of Latin America Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 336 Rest of Latin America Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 337 Rest of Latin America Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 338 Rest of Latin America Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 339 Rest of Latin America Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 340 Rest of Latin America Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 341 Rest of Latin America Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 342 Rest of Latin America Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 343 Rest of Latin America Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 344 Rest of Latin America Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 345 Rest of Latin America Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 346 Rest of Latin America Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 347 Middle East Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 348 Middle East Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 349 Middle East Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 350 Middle East Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 351 Middle East Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 352 Middle East Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 353 Middle East Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 354 Middle East Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 355 Middle East Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 356 Middle East Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 357 Middle East Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 358 Middle East Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 359 UAE Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 360 UAE Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 361 UAE Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 362 UAE Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 363 UAE Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 364 UAE Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 365 UAE Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 366 UAE Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 367 UAE Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 368 UAE Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 369 UAE Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 370 UAE Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 371 Saudi Arabia Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 372 Saudi Arabia Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 373 Saudi Arabia Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 374 Saudi Arabia Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 375 Saudi Arabia Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 376 Saudi Arabia Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 377 Saudi Arabia Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 378 Saudi Arabia Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 379 Saudi Arabia Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 380 Saudi Arabia Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 381 Saudi Arabia Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 382 Saudi Arabia Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 383 Rest of Middle East Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 384 Rest of Middle East Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 385 Rest of Middle East Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 386 Rest of Middle East Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 387 Rest of Middle East Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 388 Rest of Middle East Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 389 Rest of Middle East Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 390 Rest of Middle East Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 391 Rest of Middle East Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 392 Rest of Middle East Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 393 Rest of Middle East Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 394 Rest of Middle East Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 395 Africa Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 396 Africa Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 397 Africa Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 398 Africa Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 399 Africa Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 400 Africa Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 401 Africa Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 402 Africa Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 403 Africa Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 404 Africa Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 405 Africa Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 406 Africa Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 407 South Africa Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 408 South Africa Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 409 South Africa Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 410 South Africa Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 411 South Africa Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 412 South Africa Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 413 South Africa Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 414 South Africa Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 415 South Africa Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 416 South Africa Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 417 South Africa Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 418 South Africa Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 419 Egypt Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 420 Egypt Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 421 Egypt Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 422 Egypt Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 423 Egypt Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 424 Egypt Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 425 Egypt Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 426 Egypt Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 427 Egypt Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 428 Egypt Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 429 Egypt Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 430 Egypt Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)
TABLE 431 Rest of Africa Hepatitis D Market, by Diagnostic Tests, 2017-2022 (US$ Mn)
TABLE 432 Rest of Africa Hepatitis D Market, by Diagnostic Tests, 2023-2030 (US$ Mn)
TABLE 433 Rest of Africa Hepatitis D Market, by Treatment Modalities, 2017-2022 (US$ Mn)
TABLE 434 Rest of Africa Hepatitis D Market, by Treatment Modalities, 2023-2030 (US$ Mn)
TABLE 435 Rest of Africa Hepatitis D Market, by Antiviral Drugs, 2017-2022 (US$ Mn)
TABLE 436 Rest of Africa Hepatitis D Market, by Antiviral Drugs, 2023-2030 (US$ Mn)
TABLE 437 Rest of Africa Hepatitis D Market, by Disease Severity, 2017-2022 (US$ Mn)
TABLE 438 Rest of Africa Hepatitis D Market, by Disease Severity, 2023-2030 (US$ Mn)
TABLE 439 Rest of Africa Hepatitis D Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 440 Rest of Africa Hepatitis D Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 441 Rest of Africa Hepatitis D Market, by End-users, 2017-2022 (US$ Mn)
TABLE 442 Rest of Africa Hepatitis D Market, by End-users, 2023-2030 (US$ Mn)